Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DCC-3084 by Deciphera Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
DCC-3084 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
DCC-3084 by Deciphera Pharmaceuticals for Melanoma: Likelihood of Approval
DCC-3084 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Melanoma. According to GlobalData, Phase II...
DCC-3084 by Deciphera Pharmaceuticals for Lung Cancer: Likelihood of Approval
DCC-3084 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Lung Cancer. According to GlobalData, Phase...
Vimseltinib by Deciphera Pharmaceuticals for Tenosynovial Giant Cell Tumor: Likelihood of Approval
Vimseltinib is under clinical development by Deciphera Pharmaceuticals and currently in Pre-Registration for Tenosynovial Giant Cell Tumor. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Deciphera Pharmaceuticals's Vimseltinib?
Vimseltinib is a small molecule commercialized by Deciphera Pharmaceuticals, with a leading Phase III program in Tenosynovial Giant Cell Tumor....
DCC-3116 by Deciphera Pharmaceuticals for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval
DCC-3116 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to...
Risk adjusted net present value: What is the current valuation of Deciphera Pharmaceuticals's Vimseltinib?
Vimseltinib is a small molecule commercialized by Deciphera Pharmaceuticals, with a leading Phase III program in Tenosynovial Giant Cell Tumor....